Lexaria Bioscience (LEXX) Cash from Operations Growth (1y) (2011 - 2026)
Lexaria Bioscience (LEXX) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
85.14% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
-15.72% |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
74.39% |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
Lexaria Bioscience |
7.63 Mn |
2.11 Mn |
20,000.00 |
-44.46% |
| Date | Value |
|---|
| Feb 28, 2026 |
-44.46% |
| Nov 30, 2025 |
63.90% |
| Aug 31, 2025 |
-39.69% |
| May 31, 2025 |
-183.08% |
| Feb 28, 2025 |
-141.75% |
| Nov 30, 2024 |
-130.70% |
| Aug 31, 2024 |
-16.65% |
| May 31, 2024 |
29.11% |
| Feb 29, 2024 |
49.55% |
| Nov 30, 2023 |
5.11% |
| Aug 31, 2023 |
-37.83% |
| May 31, 2023 |
-41.84% |
| Feb 28, 2023 |
3.84% |
| Nov 30, 2022 |
-6.77% |
| Aug 31, 2022 |
-5.79% |
| May 31, 2022 |
-8.85% |
| Feb 28, 2022 |
-40.17% |
| Nov 30, 2021 |
-44.07% |
| Aug 31, 2021 |
-73.96% |
| May 31, 2021 |
-72.52% |
